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Temozolomide is a novel oral cytotoxic agent that has demon-
strated schedule-dependent clinical activity in two highly resistant
cancers, malignant glioma and metastatic melanoma, as well as
other refractory cancers (Stephens et al, 1987; Newlands et al,
1992; O’Reilly et al, 1993; Bleehan et al, 1995). Temozolomide, a
second-generation imidazotetrazine derivative, does not require
hepatic metabolism to form the cytotoxic methylating agent, 5-(3-
methyltriazen-1-y1) imidazole-4-carboxamide (MTIC), whereas
5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC)
requires hepatic activation to form MTIC (Tsang et al, 1990).
Temozolomide degrades spontaneously to MTIC at physiologic
pH and, therefore, is not subject to high interpatient variability
in its pharmacokinetics or tissue distribution (Figure 1).
Temozolomide cytotoxicity appears to be mediated principally
through methylation of DNA at the O6 position of guanine
(Catapano et al, 1987; D’Atri et al, 1995; Wedge et al, 1996),
although other mechanisms have been proposed (Liu et al, 1997).
In preclinical and clinical studies, temozolomide demonstrated
extensive tissue distribution, including penetration of the
blood–brain barrier and the cerebrospinal fluid (Patel et al, 1995;
Data on file, Schering-Plough Research Institute; Brock et al,
1997). Temozolomide has anti-tumour activity against a variety of
human tumour xenografts and murine tumour models, including
glioma, melanoma, mesothelioma, sarcoma and carcinomas of
the colon and ovary (Stevens et al, 1987; Plowman et al, 1994;
Carter et al, 1994; Friedman et al, 1995; Wedge et al, 1997a).
Additionally, temozolomide has demonstrated additive or syner-
gistic anti-tumour activity when administered in vitro with
other chemotherapeutic agents, radiation and inhibitors of poly
(ADP-ribose) polymerase and the DNA repair protein O6-alkyl-
guanine-DNA alkyltransferase (OGAT) (Wedge et al, 1996,
1997b; Liu et al, 1997). OGAT is responsible for removing DNA
adducts from the O6 position of guanine. High levels of this protein
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cause resistance to temozolomide (Catapano et al, 1987; Plowman
et al, 1994; Friedman et al, 1995; Waud et al, 1996; Wedge et al,
1997a).
Newlands et al (1992) enrolled 51 patients in a two-part phase I
study to investigate the safety and efficacy of a single oral dose of
temozolomide. In five patients investigated, the mean absolute oral
bioavailability of temozolomide was approximately 100%. Based
on the observed schedule dependency of the anti-tumour activity in
mice (Stevens et al, 1987), Newlands et al (1992) administered esca-
lating oral temozolomide once a day for 5 days to an additional 42
patients. In this population, the dose-limiting toxicity (DLT) of
temozolomide was predictable and easily controlled mild to
moderate myelosuppression (neutropenia and thrombocytopenia);
the maximum tolerated dose (MTD) was established as 200 mg m–2
day–1 (Newlands et al, 1992). Consequently, a dosage of 750–
1000 mg m–2 day–1, divided over 5 days, was recommended for
phase II studies. Clinical responses were observed in patients with
recurrent high-grade glioma, melanoma and mycosis fungoides
(Newlands et al, 1992). Subsequent phase II studies using the 5-day
schedule, repeated every 4 weeks, have confirmed clinical activity
against metastatic melanoma (Bleehan et al, 1995), recurrent high-
grade glioma and newly diagnosed astrocytomas (O’Reilly et al,
1993; Newlands et al, 1996; Bower et al, 1997; Levin et al, 1997). In
1993, Schering-Plough Research Institute began worldwide clinical
testing of temozolomide using machine-filled capsules. This prepa-
ration of temozolomide, currently available for clinical studies, is
different from the hand-filled preparation used in initial clinical
studies conducted by Newlands et al (1992). The phase I trial
reported here evaluates the safety, pharmacokinetics and anti-
tumour activity of temozolomide, administered once daily for 5
days, repeated every 28 days, using the new machine-filled prepara-
tion. Additionally, the effect of food on the pharmacokinetics of
temozolomide was assessed.
METHODS
Patients
All patients enrolled in this study were adults with a life
expectancy of at least 12 weeks, a histologically confirmed malig-
nancy and measurable or evaluable disease refractory to standard
therapy. Additional criteria included an Eastern Cooperative
Oncology Group (ECOG) performance status of > 2; white blood
cell count of ³ 4.0 ´ 109 l–1; platelet count of ³ 130 ´ 109 l–1;
haemoglobin of ³ 10 g dl–1; and serum creatinine and bilirubin
levels within the upper limit of normal.
Patients with central nervous system (CNS) metastases, uncon-
trolled infection, multiple myeloma, chronic leukaemia or bone
marrow involvement, as well as those who were pregnant or
nursing, were excluded from the study. Also excluded were
patients who had received chemotherapy, biological therapy or
radiation within 4 weeks before study initiation, patients who had
received nitrosourea or mitomycin C within 6 weeks before study
initiation or those who experienced frequent vomiting or condi-
tions that would prevent administration of oral capsules. Written
informed consent was obtained from all patients before they
entered the study.
Study evaluations/design
Prestudy evaluations included complete blood count (white blood
cells, platelets and haemoglobin), serum chemistries, chest radio-
graph, computerized tomography (CT) of the head, radiological
assessment of the tumour (CT or magnetic resonance imaging
[MRI]) and electrocardiogram (ECG). A full history was taken and
a physical examination was performed on all patients before study
entry and at each dosing cycle. Blood tests were performed at least
once a week.
Dose-escalation patients
To determine the nature and incidence of DLT and define the
MTD, temozolomide capsules (Schering-Plough Research
Institute, Kenilworth, NJ, USA) were administered orally to
cohorts of three patients at an initial dosage of 100 mg m–2 day–1
for 5 days, followed by sequential escalation to 150, 200 or
250 mg m–2 day–1 for 5 days to additional three-patient cohorts,
until a DLT was observed. The capsules contained 20 and 100 mg
of temozolomide, and daily doses were rounded up to the
nearest 20 mg to achieve 5-day dosages of 500, 750, 1000 and
1250 mg m–2 as closely as possible. No intrasubject dose escala-
tion was allowed. Patients were instructed to fast after midnight
before each dose and to continue fasting 2 h after each dose.
Patients did not receive prophylactic treatment for nausea or
vomiting in the first treatment cycle.
The DLT was defined by the Common Toxicity Criteria
(CTC) as grade 4 neutropenia (absolute neutrophil count of
< 0.5 ´ 109 l–1), grade 4 anaemia (haemoglobin of < 6.5 g dl–1), or
grade 3 thrombocytopenia (platelet count of <50 ´ 109 l–1), serum
creatinine of > 2.0 mg dl–1, or another grade 3 or 4 adverse event
(with the exception of controllable nausea or vomiting) occurring
during the first course of treatment. When a DLT was encountered
in one patient, a maximum of three additional patients was treated
at that level. If no DLT was observed in any patients, three new
patients were treated at the next-higher dosage. If a DLT was
observed in any of these patients, six patients were treated at the
next-lower dosage. When two patients experienced a DLT at a
given dosage level, no more patients were treated at this dosage
level. The MTD was defined as the dosage at which ≤ one of the
six patients experienced a DLT during the first course of treatment
and ³ two patients experienced a DLT at the next-higher level. All
patients continued treatment with temozolomide beyond cycle 1
until a DLT occurred or disease progressed. Grade 3–4 toxicities
had to be resolved before dosing was continued.
Food-effect patients
Fifteen patients were enrolled to assess the effect of food on the
relative oral bioavailability of temozolomide in a two-way
crossover design. Twelve of 15 patients met the following criteria:
correct dosage of temozolomide administered on days 1 and 2 of
cycle 1, pharmacokinetics evaluation performed on days 1 and 2 of
cycle 1, and no occurrence of vomiting within 2 h after dosing. All
patients received temozolomide, 200 mg m–2 day–1, once daily for
5 days, repeated every 4 weeks. Patients were randomized to one
of two treatment groups: group A (fasted) or group B (fed). All
patients fasted from 22:00 the previous night with water ad lib. All
patients received ondansetron, 8 mg orally, 1 h before dosing as
prophylaxis for nausea. On the first day of cycle 1, group A
patients remained fasting for 4 h after dosing, whereas group B
patients were given a modified high-fat breakfast (587 calories,
36.3 g of fat) 1 h before dosing, to be eaten within 30 min. On the
second day, patients in group A followed the day 1 schedule of
group B and vice versa.1024 M Brada et al
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Pharmacokinetics
Pharmacokinetic evaluation of temozolomide was performed
during the first treatment cycle in each study. In chilled,
heparinized tubes, 5-ml samples of blood were collected and
cooled immediately in an ice-water bath. For the dose-escalation
patients, blood samples were collected prior to dosing with temo-
zolomide and at 10, 20 and 30 min, and then 1, 1.5, 2, 2.5, 3, 4, 6,
8, 12 and 24 h post-dose on days 1 and 5. To determine the
minimum temozolomide plasma concentrations, blood samples
were also collected prior to temozolomide administration on days
2, 3 and 4. For the food-effect patients, 5 ml of blood were
collected prior to temozolomide administration and at 10, 20, 30,
45 min and then 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 h post-
dose on days 1 and 2.
To stabilize temozolomide in plasma and determine temozolo-
mide plasma concentrations, plasma was separated by centrifuga-
tion at 4°C, and 2 ml was transferred to a plastic tube containing
0.1 mL of 8.5% phosphoric acid (Shen et al, 1995; Kim et al,
1997). The acidified plasma was vortexed briefly, separated into
two equal portions and stored at –20°C. Plasma temozolomide
concentrations were determined using a validated high-
performance liquid chromatography (HPLC) assay with UV detec-
tion with a limit of quantification of 0.10 mg ml–1 and a linear
range of 0.10–20.0 mg ml–1, using a 0.5-ml plasma sample.
Additionally, urine samples were collected on day 1 and day 5
from 0–4, 4–8 and 8–24 h after dosing to determine the amount of
temozolomide excreted in the urine. Samples were collected in
containers with 2 ml of 8.5% phosphoric acid. If samples had a pH
of > 4, additional aliquots of 8.5% phosphoric acid were added
until the pH was < 4. Samples were stored at –20°C. Urinary
temozolomide concentrations were determined using a validated
HPLC assay with UV detection with a limit of quantification of
1.0 mg ml–1 and a linear range of 1.0–200 mg ml–1 using a 0.5-ml
sample. Plasma and urine assays were shown to be sensitive,
specific, linear, accurate and reproducible (Shen et al, 1995).
Pharmacokinetic parameters
Temozolomide pharmacokinetic analyses were performed using
model-independent methods. The maximum plasma concentration
(Cmax) and time to maximum plasma concentration (Tmax) were the
observed values. The terminal phase rate constant (k) was calcu-
lated as the negative of the slope of the log-linear terminal portion
of the plasma concentration time curve using linear regression.
The elimination half-life (t1/2) was calculated as t1/2 = 0.693/k. The
area under the plasma concentration curve (AUC) from time 0 to
time of final quantifiable sample (tf) was calculated using the
linear trapezoidal method from start of treatment (0 h) to the last
detectable plasma concentration and extrapolated to infinity as
AUC∞ = AUCtf + Ctf/k, where Ctf is the estimated final concentra-
tion at tf, determined by linear regression. Since temozolomide
was rapidly eliminated and did not accumulate with multiple
dosing, the AUC∞ was used to approximate AUC from 0 to 24 h
(AUC0–24 h). Total body clearance (CLF) was calculated as
CLF = Dose/AUC∞ . The apparent volume of distribution (Vd/F)
was calculated as Vd/F = [Dose/AUC∞ ]/k. The accumulation ratio
or index (R) was determined as the ratio of AUC0–24 from day
5/AUC0–24 day 1. The renal clearance (CLr) was calculated as
CLr = amount of temozolomide excreted in the urine from time
0 to24 h/AUC0–24.
Table 1 Patients’ characteristics
All patients Dose-escalation patients Food-effect patients
n = 30 (%) n = 15 (%) n = 15 (%)
Age (years)
Mean (range) 50 (25–71) 47 (25–63) 51 (27–71)
Sex
Men 20 (67) 11 (73) 9 (60)
Women 10 (33) 4 (27) 6 (40)
Prior therapies
Radiation
Yes 19 (63) 13 (87) 6 (40)
No 11 (37) 2 (13) 9 (60)
Surgery
Yes 23 (77) 13 (87) 10 (67)
No 7 (23) 2 (13) 5 (33)
Chemotherapy
Yes 20 (67) 6 (40) 14 (93)
No 10 (33) 9 (60) 1 (7)
Prior cycles of
chemotherapy 10 (33) 9 (60) 1 (7)
0 6 (20) 1 (7) 5 (33)
1 7 (23) 3 (20) 4 (27)
2 7 (23) 2 (13) 5 (33)
³3
ECOG performance
status
0 2 (7) 1 (7) 1 (7)
1 20 (67) 12 (80) 8 (53)
2 8 (27) 2 (13) 6 (40)
Percentages may not add up to 100% as a result of rounding. Data on file, Schering-Plough Research Institute.Temozolomide in refractory or relapsing malignancies 1025
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Statistical methods
Means and standard deviations were determined for temozolomide
concentration data at each time point for the dose-escalation
patients. Because the sample size was small at each dose, no statis-
tical methods were used to determine differences between doses.
Individual time points and pharmacokinetic parameters (original
scale AUC and Cmax, Tmax, k, t1/2 CLF and volumes) were evaluated
using a crossover analysis of a variance model for the food-effect
evaluations. Ninety per cent confidence intervals for the mean
difference between the two treatments were determined for the
log-transformed AUC and Cmax values. For the food-effect evalua-
tion, the effects of sequence of temozolomide administration,
subject within sequence, phase and treatment were extracted. The
pharmacokinetic parameters were analysed using the t-test and
examined for extreme values by comparing the ranges of devia-
tions generated from the t-test to the expected values derived from
the analysis of variance to see if any value exceeded 3.
Anti-tumour activity
Anti-tumour activity of temozolomide was assessed for all
patients, and disease response was defined according to World
Health Organization criteria. The best response for each patient
was derived from the objective tumour response at each cycle. A
complete response was defined as complete disappearance of all
clinically detectable malignant disease, determined by two obser-
vations not less than 4 weeks apart. A partial response was defined
as 50% decrease in the product of two perpendicular diameters of
all lesions as determined by two observations not less than 4
weeks apart. Stable disease was defined as a < 50% decrease or
a < 25% increase in the sum of the diameters of all lesions.
Progressive disease was defined as a ³ 25% increase in the size of
at least one measurable lesion or the appearance of a new lesion.
RESULTS
Patients’ characteristics
Thirty patients were enrolled in the study from 28 February, 1994,
until 27 March 1995. Fifteen patients were enrolled in the dose-
escalation portion of the study. Once the MTD was determined, an
additional 15 patients were enrolled in the food-effect portion of
the study. Patients received 120 cycles of therapy: 80 treatment
cycles for the 15 dose-escalation patients and 40 treatment cycles
for the 15 food-effect patients. Dose escalation was performed
over 5 days as follows: three patients at 500 mg m–2, three patients
at 750 mg m–2, six patients at 1000 mg m–2 and three patients at
1250 mg m–2.
The study population included patients with a range of
advanced cancers. The majority had good performance status
(73% ECOG ≤ 1) and, at the time of the study, had been diagnosed
with cancer for at least 1 year. The most common diagnosis was
glioma (10/30); the second most common was sarcoma (7/30).
Most patients with glioma (8/10) had received cranial radiation,
whereas only one had also undergone chemotherapy. Other tumour
types, in order of incidence, included mesothelioma (3/30),
ovarian carcinoma (3/30), lung carcinoma (3/30), melanoma
(2/30), adenocarcinoma (1/30) and bladder carcinoma (1/30).
Most patients (20/30) had received prior treatment with at least
1–2 regimens of chemotherapy (range 1–5 regimens). The
majority of patients (77%) had had prior surgery. Of the 30
patients enrolled, 27 received five consecutive daily doses of
temozolomide during each cycle. Patient characteristics are
detailed in Table 1.
Safety
Haematological toxicity
Patients who completed at least one cycle of temozolomide or had
a DLT during cycle 1 were evaluated for safety. No cumulative
toxicity was observed at any dosage level when temozolomide was
administered on a once-daily, 5-day schedule. Myelosuppression
occurred in cycle 1 or 2 with a nadir occurring late in the cycle
(day 24 to 26 for thrombocytopenia and days 30–31 for
neutropenia) and rapidly recovered. Although 91% of the cycles
were administered without evidence of haematological toxicity
prior to dosing, five patients required a dosage reduction when
haematological toxicities reappeared: three dose-escalation
patients who received 1250 mg m–2 and two food-effect patients
Table 2 Haematological toxicities: patients reporting adverse events after
cycle 1
Dose-escalation
n WHO grade
Dose level (mg m–2)1 2 3 4
Thrombocytopenia
500 3 0 0 0 0
750 3 0 0 0 0
1000 6 0 0 0 0
1250 3 0 0 0 2
Total 15 0 0 0 2 (13%)
Anaemia
500 3 0 0 0 0
750 3 0 0 0 0
1000 6 0 0 0 1
1250 3 0 0 1 0
Total 15 0 0 1 (6%) 1 (6%)
Neutropenia
500 3 0 0 0 0
750 3 0 0 0 0
1000 6 0 0 0 0
1250 3 0 0 2 0
Total 15 0 0 2 (13%) 0
Table 3 Non-haematological toxicities: number (%) of treatment-related
adverse events (grades 1–4) reported for cycle 1
Adverse events Dose escalation Food effects
Fatigue 2 (13) 7 (47)
Headache 4 (27) 6 (40)
Pain 2 (13) –
Constipation 4 (27) 5 (33)
Nausea 12 (80) 8 (53)
Vomiting 11 (73) 4 (27)
Somnolence 5 (33) –
Dizziness – 1 (7)
Fever – 1 (7)
Anorexia – 3 (20)
Diarrhoea – 1 (7)1026 M Brada et al
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required dosage reduction to prevent haematological toxicity. The
most common reason for discontinuation of treatment was
progression of disease. Three dose-escalation patients discon-
tinued the study: one patient’s treatment was discontinued for an
adverse event (pain in the shoulder) not attributable to the drug;
one patient died at the end of the first cycle because of tumour
progression; and one patient was removed from the study for
administrative reasons. One patient in the food-effect portion of
the study elected to discontinue treatment.
Dose-escalation patients
Fifty-three of 80 (67%) cycles of therapy administered to dose-
escalation patients were evaluated for haematological toxicity.
Dose-limiting myelosuppression, particularly thrombocytopenia,
occurred at the 1250 mg m–2 dosage level. When temozolomide
was escalated to 1250 mg m–2, two of three patients developed
CTC grade 4 thrombocytopenia, with a nadir at days 24–25 of
cycle 1, and CTC grade 3 neutropenia, with a nadir on days 29 and
36. After a dosage reduction to 1000 mg m–2, one patient remained
thrombocytopenic (grade 4) and required a further reduction. Two
of the three patients demonstrated grade 2 thrombocytopenia. No
evidence of cumulative toxicity was reported at any dosage level
in patients treated on a 5-day schedule.
Food-effect patients
Grade 3 thrombocytopenia was observed after cycles 1 and 2
in 20% of patients (3/15) and was associated with grade 3
neutropenia in two patients. This was not significantly different
from the incidence of grade 4 thrombocytopenia observed in the
MTD cohort of the dose-escalation patients (17%). The dosage
was decreased to 750 mg m–2 in one patient with no further toxicity
observed. Patients in the food-effect cohort had no grade 4 haema-
tological toxicities.
Non-haematological toxicity
All non-haematological toxicities were mild (CTC grade 1 or 2)
and easily controlled. Table 3 presents a summary of all treatment-
related non-haematological adverse events that occurred in more
than one patient during the first cycle of treatment.
Dose-escalation patients
The most frequent non-haematological toxicities during the first
cycle for the dose-escalation patients were nausea (80%) and
vomiting (73%), which occurred at all dosage levels. These
toxicities usually occurred on day 1 and were considered mild to
moderate in most cases. As anti-emetics were withheld until CTC
Grade 3–4 nausea and vomiting occurred, this represents the actual
incidence of nausea and vomiting. Gastrointestinal disturbance
was generally transient, lasting an average of 1–2 days, and was
relieved by ondansetron alone or in combination with metoclo-
pramide or haloperidol. Other mild treatment-related adverse
events for the first cycle included somnolence (33%), constipation
(27%) and headache (27%). In all cases, the event was rated as
mild to moderate. The adverse reaction profile as well as incidence
and severity of adverse events remained the same in subsequent
cycles.
Food-effect patients
The most common treatment-related non-haematological adverse
events during the first cycle of treatment for patients in the food-
effect portion of the study were nausea (53%), fatigue (47%),
headache (40%), constipation (33%) and vomiting (27%). The
majority of adverse events, including nausea and vomiting, were
mild to moderate and generally consistent with those observed for
the dose-escalation patients.
Table 4 Summary of pharmacokinetic parameters from dose-escalation patients (n = 15)
Temozolomide
100 mg m–2 day–1 150 mg m–2 day–1 200 mg m–2 day–1 250 mg m–2 day–1
(500 mg m–2 (750 mg m–2 (1000 mg m–2 (1250 mg m–2
cycle–1) cycle–1) cycle–1) cycle–1)
Parameter Unit Meana % CV Meana % CV Meanb % CV Meana % CV
Day 1
Cmax mg ml–1 7.00 21 5.84 56 13.9 46 13.7 17
Tmax h 0.50 0 0.94 62 0.94 87 1.00 0
AUC0–24 h mg h ml–1 15.5 8 17.0 35 33.2 15 43.0 7
AUCinfinity mg h ml–1 15.5 8 17.0 35 33.2 15 43.0 7
T1/2 h 1.72 4 1.75 4 1.79 6 1.91 8
ClT/F ml min–1 208 8 310 32 197 22 180 18
ClT/F (kg) ml min–1 kg–1 2.48 10 4.12 45 2.54 17 2.43 5
Vd/F l 31.0 11 47.2 36 30.5 26 30.0 25
Vd/F (kg) l kg–1 0.37 9 0.63 49 0.39 13 0.40 4
Day 5
Cmax mg m–1 6.92 30 5.71 27 13.0 39 12.2 15
Tmax h 0.39 25 1.17 25 1.25 55 1.33 78
AUC0–24 h mg h ml–1 16.7 9 16.8 13 34.5 15 42.6 3
T1/2 h 1.81 4 1.72 15 1.79 9 1.85 5
ClT/F ml min–1 207 9 293 10 189 20 181 14
ClT/F (kg) ml min–1 kg–1 2.48 13 3.84 23 2.45 18 2.45 9
Vd/F l 32.6 13 43.2 5 29.6 27 29.0 17
Vd/F (kg) l kg–1 0.39 15 0.56 20 0.38 16 0.39 9
R 1.00 4 1.04 22 1.04 8 0.99 4
an = 3. bn = 6. % CV = per cent coefficient of variation.Pharmacokinetics
Dose escalation
Single- and multiple-dose pharmacokinetics were assessed for all
15 dose-escalation patients on days 1 and 5 of cycle 1 (Table 4).
Temozolomide was absorbed rapidly after oral administration of a
100–250 mg m–2 dose of temozolomide, with a mean Cmax of
5.71–13.9 mg ml–1 achieved within approximately 1 h (range
0.33–2.5 h) following oral administration. Elimination of temo-
zolomide was rapid, with a mean elimination t1/2 of 1.8 h. There
was no evidence of accumulation with multiple dosing. The
minimum observed plasma concentrations on days 1 through 5
were below the limit of quantification of the assay, and the mean
accumulation index at each dosage level was 1.0. Dosage-related
increases in Cmax, AUCtf, AUC0–24, and AUC ∞ were observed, and
the plasma concentration of temozolomide was similar on days 1
and 5 (Figure 2). The interpatient variability in the AUC observed
on day 1 was small (% coefficient of variation [CV] ≤ 15) except
for the 150 mg m–2 dosage level (% CV = 35). The higher vari-
ability observed in this group was attributed to the considerably
lower AUC value for one of the three patients in that group. Mean
CLT/F values (range 2.43–4.12 ml min–1 kg–1) were similar on days
1 and 5 and were independent of the dosage of temozolomide. The
mean Vd/f ranged from 0.37 to 0.63 l kg–1, suggesting that temo-
zolomide distribution approximates that of total body water.
The recovery of unchanged temozolomide in the urine was also
dosage related and ranged from 4.8% to 9.6% of the administered
dose over the 24-h collection period. The mean CLR (range
0.12–0.26 ml min–1 kg–1) was dosage-independent and small in
comparison with CLT/F as a result of the rapid and extensive degra-
dation of temozolomide at physiologic pH. The mean values for
urinary excretion and CLR for temozolomide are presented in
Table 5.
Effect of food
The administration of temozolomide after a modified high-fat
meal had an effect on the rate and extent of temozolomide
absorption (Table 6). The mean Tmax increased from 1.07 to 2.25 h
(P = 0.01), the Cmax decreased from 9.55 mg ml–1 to 6.51 mg ml–1,
and the mean AUC0–24 decreased from 30.8 to 28.1 (P = 0.048)
when temozolomide was administered after a meal. Although
these data indicate that the presence of food results in a decrease in
the rate and extent of absorption of temozolomide, the reduction in
AUC was small (9.1%) and the AUC confidence levels were
within 80–125% (AUC0–24 range, 84–98%).
Anti-tumour activity
Evidence of clinical activity was observed in 33% (10/30) of
patients enrolled in the study. Stable disease was reported in nine
Temozolomide in refractory or relapsing malignancies 1027
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Figure 2 Representative plasma-concentration profile for days 1 and 5 after
oral administration of temozolomide 200 mg m–2 in a patient with advanced
cancer
Table 5 Mean urinary excretion (mg) and CLR of temozolomide on days 1 and 5 following oral administration to adult patients with advanced cancer
100 mg m–2 day–1 150 mg m–2 day–1 200 mg m–2 day–1 250 mg m–2 day–1
Day 1
Time (h) Mean % CV Mean (n = 3) % Mean (n = 6) % Mean %
(n = 3) CV CV (n = 3) CV
4 7.71 40 11.9 66 20.5b 28 25.8 16
8 1.94 36 4.33a 29 7.73 44 5.15 94
24 0.00 – 1.65 102 2.32 107 1.60 117
AUC0–24 h (mg h ml–1) 15.50 8 17.0a 35 33.2 15 43.0 7
Clr (kg) (ml min–1 kg) 0.12 42 0.21a 10 0.19b 15 0.17 8
Day 5
Time (h) Mean % CV Mean (n = 3) % Mean (n = 6) % Mean %
(n = 3) CV CV (n = 3) CV
4 8.26 24 15.3 40 21.3 48 29.6 54
8 1.51 12 5.01 45 7.16 64 11.4 55
24 0.36 173 0.63 173 1.61 96 3.52 100
AUC0–24 h (mg h ml–1) 16.7 9 16.8 13 34.5 15 42.6 3
CLr (kg) (ml min–1 kg) 0.12 29 0.26 16 0.18 45 0.23 17
a n = 2. bn = 5.1028 M Brada et al
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patients: four with glioma, three with sarcoma, one with mesothe-
lioma and one with ovarian carcinoma. One patient with malignant
glioma who was treated at the 1000 mg m–2 dose level had a partial
response that lasted 6.3 months. Four patients were not assessed
for objective response to therapy and consequently could not be
evaluated. Median time to disease progression for the four glioma
patients with stable disease was 8.7 months (range 4.1–13.4
months). The median time to progression for the three sarcoma
patients who experienced disease stabilization was 8.4 months
(range 4.1–11.5 months).
DISCUSSION
Newlands et al (1992) demonstrated the schedule-dependent
clinical activity of temozolomide in glioma and melanoma. This
study showed that temozolomide, when administered on an oral
5-day schedule as machine-filled capsules currently available for
phase II clinical studies, is similar in safety and efficacy to the
hand-filled capsules used in the original studies (Newlands et al,
1992).
The DLT, a rapidly reversible and noncumulative delayed
thrombocytopenia, was observed at the 250 mg m–2 day–1 dosage
level when given on a 5-day schedule, repeated every 28 days.
These results are similar to the results of the first phase I study in
advanced cancer, which also indicated that DLT was thrombo-
cytopenia (Newlands et al, 1992).
The results reported here are consistent with results of a phase I
study reported by the National Cancer Institute that evaluated the
safety of the machine-filled temozolomide capsules in patients
stratified on the basis of prior exposure to nitrosourea (Dhodapkar
et al, 1997). Patients received the machine-filled capsules of temo-
zolomide once daily for 5 days, every 28 days. The DLT for
patients with and without prior exposure to nitrosourea was
thrombocytopenia. The MTD for patients with prior exposure to
nitrosourea was 150 mg m–2, and the MTD for patients without
prior exposure was 250 mg m–2 (Dhodapkar et al, 1997). The MTD
for temozolomide was also established as 150 mg m–2 in a similar
study that used machine-filled capsules to evaluate the safety and
tolerance of temozolomide in 24 patients who were stratified by
extent of prior treatment (Reidenberg, 1996). All but one of 24
patients had been pretreated with chemotherapy regimen, with or
without radiation. In contrast, the majority of patients in the
present dose-escalation study either had had no prior
chemotherapy or had been minimally pretreated (fewer than two
regimens), which may account for the slight difference observed
between these studies in the dosage level that caused DLT and
MTD. The results of the study reported here indicate that a
200 mg m–2 dosage of temozolomide given on a 5-day schedule
and repeated every 28 days is an appropriate dosage for future
phase II studies for patients who are not pretreated with radiation
and/or chemotherapy. Previous studies suggested that patients who
are pretreated with chemotherapy receive a lower starting dosage
of temozolomide (i.e. 150 mg m–2), which can be escalated to
200 mg m–2 in subsequent courses in the absence of grade 3 or 4
myelosuppression (Reidenberg, 1996; Dhodapkar et al, 1997).
The most common non-haematological side-effects associated
with temozolomide were gastrointestinal toxicity with a relatively
rapid onset and short duration. In all instances, it was mild to
moderate and clinically manageable with standard anti-emetics.
This profile is consistent with the side-effects observed in other
phase I clinical studies (Newlands et al, 1992; Reidenberg, 1996;
Dhodapkar et al, 1997).
The results indicated that the pharmacokinetics of temozolo-
mide is linear and reproducible with minimal intrapatient and
interpatient variability. Temozolomide was rapidly and extensively
absorbed with mean peak plasma concentrations achieved within
0.33–2.5 h (mean, approximately 1 h) after oral dosing and rapidly
eliminated with a mean t1/2 of 1.8 h. The Cmax and AUC were
similar after single and multiple doses, indicating that temozolo-
mide does not accumulate in the plasma after multiple dosing.
CLF was independent of dosage, indicating that temozolomide
pharmacokinetics are linear. Additionally, low interpatient vari-
ability in temozolomide pharmacokinetics also reflects the fact
that temozolomide does not require hepatic metabolism for
conversion to MTIC. These study results indicate that the
machine-filled capsule preparation of temozolomide demonstrates
pharmacokinetics and clinical characteristics similar to those of
the hand-filled capsules in the previous phase I study (Newlands
et al, 1992), which demonstrated that temozolomide was essen-
tially 100% bioavailable.
The results of this study indicate that emesis that occurred on
day 1 did not affect the plasma concentration of temozolomide.
Emesis was observed on day 1 in 11 of the 15 patients.
Subsequently, all patients were given antiemetics to control nausea
and vomiting post-dose on day 1 and predose on day 5. As a result,
no emesis was observed on day 5. Since the day 1 and day 5
concentration versus time profiles were similar, emesis on day 1
and the administration of ondansetron predose on day 5 did not
appear to affect the pharmacokinetics of temozolomide.
Administration of temozolomide after food resulted in a small
decrease in its oral bioavailability. Peak plasma concentrations for
the fasted patients were observed within 0.5 and 2 h (mean, 1.07 h)
post-dose, whereas peak plasma concentrations for the fed patients
were observed within 0.75–4 h (mean, 2.25 h) post-dose. Thus,
Table 6 Summary of mean pharmacokinetic parameters, point estimates and 90% confidence intervals from food-effects patients following oral administration
of temozolomide (200 mg m–2)
Group A Group B
(fasted) % (fed) % Point estimate 90% Confidence
Parameter Units n = 6 CV P (%)a intervalsb
Cmax mg ml–1 9.55 18 6.51 27 0.001c 67.3 58–79
AUCtf mg h ml–1 30.0 14 27.3 16 0.029c 90.9 85–97
AUC0–24 h mg h ml–1 30.8 14 28.1 16 0.048c 90.9 84–98
Tmax h 1.07 40 2.25 48 0.010d ––
a Expressed as a percent of treatment group A (fasted). bBased on log-transformed data; a = 0.05. cBased on log-transformed data. dBased on linear-scale data.Temozolomide in refractory or relapsing malignancies 1029
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the mean Cmax decreased by 33% when temozolomide was
administered with a meal. However, the extent of absorption was
only slightly reduced (9%) for the fed patients as compared with
the fasted patients. The relative oral bioavailability under fed
conditions ranged from 64% to 108%, with only three of the 12
patients in the fed group having a relative oral bioavailability that
was ≤ 80%. Although the reduction in the extent of absorption was
statistically significant (P = 0.048), the decrease was small and the
AUC confidence intervals were within the 80–125% guidelines for
bioequivalence. Because the effect on the AUC is small, it is
unlikely that the slight reduction observed in the oral bioavail-
ability of temozolomide in the presence of a meal has any clinical
significance. The incidence of emesis was similar in the fed and
fasted groups, further indicating that temozolomide can be taken
with food.
There was an objective response in one patient with glioma.
Nine patients, including four with glioma, three with sarcoma, one
with ovarian carcinoma and one with mesothelioma, had stable
disease. Similar antitumor activity has been observed in phase I
trials in patients with glioma, melanoma and mycosis fungoides
(Newlands et al, 1992; Dhodapkar et al, 1997). Temozolomide has
demonstrated clinical activity in phase II trials in metastatic
melanoma (Bleehan et al, 1995) and recurrent high-grade glioma
(O’Reilly et al, 1993; Newlands et al, 1996; Bower et al, 1997).
In contrast to DTIC and other alkylating agents that are
prodrugs, temozolomide has the advantage of spontaneous
chemical conversion to its active species, MTIC, and thus does not
require hepatic metabolism. This conversion is controlled only by
the pH of the local environment (Denny et al, 1994). This property
will potentially result in lower patient-to-patient variability when
assessing the pharmacokinetics of temozolomide. Additionally,
the spontaneous conversion of temozolomide to MTIC should not
be affected by the co-administration of potentially hepatotoxic
agents (e.g. high-dose chemotherapy for bone marrow transplanta-
tion) and reduce the potential for interactions with other thera-
peutic agents.
Although temozolomide and DTIC share the same reactive
moiety, MTIC, temozolomide differs from DTIC in its ability to
penetrate the blood–brain barrier and cerebrospinal fluid (Patel et
al, 1995; Data on file, Schering-Plough Research Institute; Brock
et al, 1997). As a result, temozolomide is currently being explored
for the treatment of primary and metastatic CNS tumours, particu-
larly tumours with a high propensity for CNS metastasis, such as
malignant melanoma, small-cell lung carcinoma, breast carcinoma
and high-grade lymphoma.
In summary, this phase I study demonstrated an acceptable
safety profile for the new chemotherapeutic agent temozolomide.
The pharmacokinetics are reproducible with low interpatient vari-
ability and are only slightly modified by food. The DLT is throm-
bocytopenia that is reversible and non-cumulative. Temozolomide
is well tolerated with manageable gastrointestinal toxicities.
Unlike many other chemotherapeutic agents, temozolomide does
not cause alopecia or diarrhoea, which can have a significant effect
on the patient’s quality of life. Temozolomide’s broad spectrum of
antitumour activity is encouraging and is being further confirmed
in ongoing randomized phase II/III trials. Temozolomide is a well-
tolerated novel oral cytotoxic agent with convenient once-daily
oral administration for 5 days, a schedule that may prove to be
effective in the treatment of highly resistant cancers such as recur-
rent glioma and metastatic melanoma.
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